DRUG

Bright Minds Biosciences Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website brightmindsbio.com
Employees(FY) -
ISIN CA10919W4056

Performance

-17.67%

-30.8%

+3102.63%

+2870.0%

+2184.62%

YTD

+2513.39%

Profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of DRUG 2024-11-20

The stock's indicators reflect a neutral sentiment, with the Moving Average Score at 43, Oscillators Score at 40, and Technical Score at 41, suggesting a lack of strong bullish or bearish momentum. Overall, these scores indicate that the stock is currently in a consolidation phase, warranting cautious observation before making any trading decisi...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of DRUG

Stock Rank

Recent News & Updates

2024-11-05 17:30
Bright Minds Biosciences Secures $35 Million Investment(Yahoo Finance)
2024-11-04 01:41
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement(Globenewswire)
2024-10-20 20:30
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data(Globenewswire)
2024-10-17 18:50
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement(Globenewswire)
2024-10-15 22:45
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models(Globenewswire)
2024-10-15 21:20
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA Technology(Globenewswire)
2024-10-15 17:57
Biotech stock tumbles after unexplained 1,446% gain(Yahoo Finance)
2024-10-15 09:09
Bright Minds is Unaware of Any Material Changes(Newsfilecorp)
2024-10-02 21:00
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events(Globenewswire)
2024-09-18 22:00
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th(Globenewswire)
2024-09-11 20:00
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy(Prnewswire)
2024-08-11 19:30
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-05-19 23:53
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024(Investorplace)
2023-12-06 04:08
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management(Yahoo Finance)
2023-08-07 18:50
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101(Yahoo Finance)
2023-07-19 18:50
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101(Yahoo Finance)
2023-07-10 18:50
Bright Minds Announces Effective Date of Share Consolidation(Yahoo Finance)
2023-06-21 18:50
Bright Minds Announces Proposed Share Consolidation(Yahoo Finance)
2023-04-18 18:50
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202(Yahoo Finance)
2023-04-09 18:50
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research(Yahoo Finance)
2023-02-26 17:50
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023(Yahoo Finance)
2023-02-16 17:50
Bright Minds Biosciences Announces Non-Executive Director Appointment(Yahoo Finance)
2023-02-08 03:05
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements(Yahoo Finance)
2023-01-27 03:05
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency(Yahoo Finance)
2023-01-09 03:05
Bright Minds Biosciences Announces Resignation of Board Member(Yahoo Finance)
2022-12-02 06:07
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement(Yahoo Finance)
2022-11-27 17:50
Bright Minds Biosciences Announces Non-Brokered Private Placement(Yahoo Finance)
2022-11-22 22:35
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer(Yahoo Finance)
2022-09-06 18:50
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors(Yahoo Finance)
2022-08-30 18:50
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.